Palvella Therapeutics, Inc.
PVLA
$23.44
-$1.13-4.60%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.82M | 1.88M | 1.47M | 1.12M | 717.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.37M | 5.06M | 2.91M | 2.33M | 1.42M |
| Operating Income | -4.37M | -5.06M | -2.91M | -2.33M | -1.42M |
| Income Before Tax | -3.95M | -6.78M | -4.17M | -3.35M | 20.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.95M | -6.78M | -4.17M | -3.35M | 20.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.95M | -6.78M | -4.17M | -3.35M | 20.54M |
| EBIT | -4.37M | -5.06M | -2.91M | -2.33M | -1.42M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.31 | -1.22 | -0.76 | -0.62 | 1.10 |
| Normalized Basic EPS | -0.29 | -0.74 | -0.46 | -0.37 | -0.28 |
| EPS Diluted | -0.31 | -1.22 | -0.76 | -0.62 | 1.10 |
| Normalized Diluted EPS | -0.29 | -0.74 | -0.46 | -0.37 | -0.28 |
| Average Basic Shares Outstanding | 11.01M | 5.72M | 5.72M | 5.72M | 5.72M |
| Average Diluted Shares Outstanding | 11.01M | 5.72M | 5.72M | 5.72M | 5.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |